Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enpatoran long-term extension study in lupus erythematosus with skin manifestations
ChiCTR2600134707Phase 3Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of enpatoran in lupus erythematosus (SLE), sponsored by West China Hospital of Sichuan University. Primary endpoint: Long-term safety of Enpatoran. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
enpatoran
03
Conditions
lupus erythematosus (SLE)
Beyond the preview
Go deeper on ChiCTR2600134707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134707.